This article has been updated to include a statement from Exact Sciences.

NEW YORK (GenomeWeb) – Exact Sciences' shares fell as much as 7 percent on Monday after short-seller Citron Research released a report calling the company's Cologuard colon cancer test "inferior" and claimed it had proof that the company's stock "will soon be cut in half."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.